Cheniere Energy Partners beats revenue but misses on earnings
We haven't written up this one. Investing.com has the full story — the link below goes straight to it.
More in Finance & Markets
Is IonQ Stock a Buy for 2027?
IonQ's revenue is growing quickly, but the company is still a long way from profitability.
Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again
Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
